Immunomedics for small cell lung cancer
-
Last Update: 2013-12-06
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: China Council for the promotion of drugs 2013-11-07 us time on December 4, 2013, immunomedics announced that it had received the notice that immu-132, an antibody conjugate drug approved by the orphan Product Development Office of the US Food and Drug Administration (FDA) for the treatment of solid tumor small cell lung cancer, was an orphan drug A biopharmaceutical company focused on the development of monoclonal antibody based targeted drugs for cancer, autoimmune diseases and other serious diseases "In addition to small cell lung cancer, the drug is currently in phase II clinical development for certain types of solid tumors," said Cynthia Sullivan, President and CEO of immunomedics In early phase I trials, patients with small cell lung cancer, colorectal cancer, and triple negative breast cancer developed a local response to immu-132 Immu-132 is an active antibody containing humanized anti-trop-2 antibody and hrs7, which is linked to SN-38 by pH sensitivity SN-38 is an active metabolite of irinotecan It is a standard therapy for metastatic colorectal cancer, but it is mainly toxic to gastrointestinal tract and blood By attaching SN-38 to tumor targeted antibody, SN-38 can be transported to tumor, which can double the therapeutic effect and reduce systemic toxicity Original link: http://www.rttnews.com/2233942/immunomedics-immu-132-gets-orphan-drug-status-for-small-cell-lung-cancer.aspx
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
